Utilizing biomarkers in atrial fibrillation: the pros and cons

Wern Yew Ding¹, Garry McDowell^{1

2}, Gregory Y H Lip^{1

3}

Affiliations

¹ Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.
² School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
³ Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Editorial

Wern Yew Ding et al. Cardiovasc Res. 2022.

. 2022 Jul 20;118(9):2035-2036.

doi: 10.1093/cvr/cvab283.

Wern Yew Ding¹, Garry McDowell^{1

2}, Gregory Y H Lip^{1

3}

¹ Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.
² School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
³ Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

No abstract available

Comment on

Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.
Pol T, Hijazi Z, Lindbäck J, Oldgren J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Siegbahn A, Wallentin L. Pol T, et al. Cardiovasc Res. 2022 Jul 20;118(9):2112-2123. doi: 10.1093/cvr/cvab262. Cardiovasc Res. 2022. PMID: 34358298 Free PMC article. Clinical Trial.